Possible Antiretroviral Therapy‐Warfarin Drug Interaction
Authors:
- 1 July 2008
- journal article
- case report
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 28 (7) , 945-949
Abstract
Highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) has resulted in significant morbidity and mortality reductions. Lifelong antiretroviral therapy must be incorporated into each patient's medical regimen. Patients with HIV may also have simultaneous chronic medical conditions, resulting in the possibility of complex drug‐drug interactions. We report a possible drug‐drug interaction between HAART and warfarin in two patients, as assessed by the Naranjo adverse drug reaction probability scale and the Drug Interaction probability scale. Both patients' pharmacotherapy regimens included a nonnucleoside reverse transcriptase inhibitor (NNRTI), nevirapine, or a protease inhibitor, nelfinavir or lopinavirritonavir, and two nucleoside analogs. In both patients, high warfarin doses were required to maintain therapeutic international normalized ratios (INRs). Warfarin has two enantiomers, R‐and S‐warfarin, which are substrates primarily of cytochrome P450 (CYP) 3A4 (R‐warfarin), CYP1A2 (R‐warfarin), and CYP2C9 (S‐warfarin). Protease inhibitors and NNRTIs have variable effects on CYP: induction, inhibition, or mixed. The increased warfarin doses required in these two patients may have been caused by induction of CYP3A4 by nevirapine, CYP2C9 by nelfinavir, or CYP2C9 by lopinavir‐ritonavir. Thus, practitioners should prudently monitor INRs in patients receiving warfarin with concomitant HAART that includes either a protease inhibitor or an NNRTI.Keywords
This publication has 18 references indexed in Scilit:
- Pharmacokinetic study of the interaction between itraconazole and nevirapineEuropean Journal of Clinical Pharmacology, 2007
- Lopinavir/Ritonavir Induces the Hepatic Activity of Cytochrome P450 Enzymes CYP2C9, CYP2C19, and CYP1A2 But Inhibits the Hepatic and Intestinal Activity of CYP3A as Measured by a Phenotyping Drug Cocktail in Healthy VolunteersJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Comparisons of Causes of Death and Mortality Rates Among HIV-Infected PersonsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Systematic Overview of Warfarin and Its Drug and Food InteractionsArchives of internal medicine (1960), 2005
- Anticonvulsant and Antiretroviral InteractionsAnnals of Pharmacotherapy, 2004
- Interactions among Drugs for HIV and Opportunistic InfectionsNew England Journal of Medicine, 2001
- Pharmacogenetics of Warfarin Elimination and its Clinical ImplicationsClinical Pharmacokinetics, 2001
- A Generalized Seizure Following Initiation of Nelfinavir in a Patient with Human Immunodeficiency Virus Type 1 Infection, Suspected due to Interaction between Nelfinavir and Phenytoin.Internal Medicine, 1999
- Cytochrome P4502C9: an enzyme of major importance in human drug metabolismBritish Journal of Clinical Pharmacology, 1998
- Human P450 metabolism of warfarinPharmacology & Therapeutics, 1997